BTIG rates Kazia Therapeutics Buy and raises price target to $40
AI Summary- BTIG gave Kazia Therapeutics a Buy rating and raised its price target.
- The target increased to $40 from $34, while paxalisib showed 52% tumor reduction.
- Kazia's lead drug produced the reduction in preclinical colorectal ca...